Stay updated on Ibrutinib and Nivolumab Trial in Hodgkin Lymphoma

Sign up to get notified when there's something new on the Ibrutinib and Nivolumab Trial in Hodgkin Lymphoma page.
Latest website image capture
Clouds background image

Latest updates to the Ibrutinib and Nivolumab Trial in Hodgkin Lymphoma page

  1. Check
    3 days ago
    Change Detected
    Summary
    The record now displays details for the phase 2 study of ibrutinib and nivolumab for relapsed or refractory classical Hodgkin lymphoma, including its eligibility criteria, treatment plan, locations, and outcome measures.
    Difference
    52%
    Check dated 2026-11-09T13:42:33.000Z thumbnail image
  2. Check
    10 days ago
    Change Detected
    Summary
    The site footer now shows revision v3.8.0 instead of v3.7.2.
    Difference
    0.2%
    Check dated 2026-11-02T13:42:01.000Z thumbnail image
  3. Check
    17 days ago
    Change Detected
    Summary
    A site-wide banner announces NIH website transition updates and notes that federal agencies are using “Super Intelligence” in place of “Artificial Intelligence.”
    Difference
    1%
    Check dated 2026-10-26T16:31:59.000Z thumbnail image
  4. Check
    24 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov page remains a 403 Forbidden error, and its footer revision identifier was updated from v3.7.1 to v3.7.2.
    Difference
    0.2%
    Check dated 2026-10-19T21:43:43.000Z thumbnail image
  5. Check
    31 days ago
    Change Detected
    Summary
    The footer revision identifier changes from v3.7.0 to v3.7.1, while the page continues to show a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-13T04:14:45.000Z thumbnail image
  6. Check
    52 days ago
    Change Detected
    Summary
    The study page now displays a 403 Forbidden error instead of the trial details, making the study information inaccessible and disrupting navigation to related study data.
    Difference
    19%
    Check dated 2026-09-21T22:30:04.000Z thumbnail image

Stay in the know with updates to Ibrutinib and Nivolumab Trial in Hodgkin Lymphoma

Enter your email address, and we'll notify you when there's something new on the Ibrutinib and Nivolumab Trial in Hodgkin Lymphoma page.